Entrada Therapeutics, Inc. (TRDA)
6.57
-0.54
(-7.59%)
USD |
NASDAQ |
Sep 10, 13:28
Entrada Therapeutics Profit Margin (Quarterly) : -4.76K% for June 30, 2026
Profit Margin (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -4.76K% |
| March 31, 2026 | -4.54K% |
| December 31, 2025 | -3.01K% |
| September 30, 2025 | -2.73K% |
| June 30, 2025 | -2.21K% |
| March 31, 2025 | -84.39% |
| December 31, 2024 | 3.02% |
| Date | Value |
|---|---|
| September 30, 2024 | -71.70% |
| June 30, 2024 | 58.11% |
| March 31, 2024 | 39.74% |
| December 31, 2023 | -22.81% |
| September 30, 2023 | 81.08% |
| June 30, 2023 | -142.7% |
| March 31, 2023 | -26.42% |
Profit Margin Definition
Profit Margin is calculated using Net Income/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into profit. An analyst looking at profit margin might look for a higher profit margin relative to other comparable companies as well as a profit margin that is growing.
Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Profit Margin (Quarterly) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | -237.8% |
| Oncolytics Biotech, Inc. | -- |
| Sangamo Therapeutics, Inc. | -2.15K% |
| Sarepta Therapeutics, Inc. | -1.22% |
| Anixa Biosciences, Inc. | -- |
Profit Margin (Quarterly) Related Metrics
| Return on Equity | -54.15% |
| Return on Assets | -44.24% |
| Return on Invested Capital | -46.38% |
| Gross Profit Margin (Quarterly) | 10.91% |
| Operating Margin (Quarterly) | -5.01K% |
| Return on Net Operating Assets | -238.9% |